Nicolae Bacalbasa Carol Davila University Of Medicine and Pharmacy

Similar documents
Surgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14

Dr Adam Bartlett. General Surgeon Senior Lecturer University of Auckland Auckland City Hospital

CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer

Neoadjuvant Treatment of. of Radiotherapy

Jose Ramos. Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma

Management of Colorectal Liver Metastases

ITALIAN SURGICAL SOCIETY ENDOCRINE SURGERY SCHOOL LIVER METASTASIS FROM NEUROENDOCRINE TUMORS

Management of colorectal cancer liver metastases

MANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011

Embolotherapy for Cholangiocarcinoma: 2016 Update

State of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options

Ideal neo-adjuvant Chemotherapy in breast ca. Dr Khanyile Department of Medical Oncology, University of Pretoria

THORACIC MALIGNANCIES

Primary tumor with synchronous metastases

Radiation Therapy for the Oncologist in Breast Cancer

Pulmonary Resection for Metastases from Colorectal Cancer

How to integrate surgery in the treatment of patients with liver-only metastatic disease

16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes

Index. Note: Page numbers of article titles are in boldface type.

Treatment of Colorectal Liver Metastases State of the Art

Management of Liver Metastasis from Colorectal Carcinoma. Aisha White, M.D. SUNY Downstate Division of Transplantation

Colon Cancer Liver Metastases: Liver-Directed Therapy

Treatment of Locally Advanced Rectal Cancer: Current Concepts

IJC International Journal of Cancer

Surgical Management of Pancreatic Cancer

Synchronous Hepatic Cryotherapy and Resection

Hepatic Resection is Safe for Metachronous Hepatic Metastases from Ovarian Cancer

Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer

Long-Term Survival Analysis of Korean Breast Cancer Patients at a Single Center: Improving Outcome Over Time

All India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology

Aggressive surgery in the multimodality treatment of liver metastases from colorectal cancer

Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies

Pulmonary metastases of breast cancer. When is resection indicated?

The Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer

Prof. Dr. Aydın ÖZSARAN

Resection of liver limited resectable metastases Upfront, neoadjuvant and repeat hepatectomy

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients

Why Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients

Metastasectomy for Melanoma What s the Evidence and When Do We Stop?

Sentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD

When to Integrate Surgery for Metatstatic Urothelial Cancers

The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Surgical Management of Pulmonary Metastases. Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital

BRUSTKREBSNACHSORGE Program Surveillance in women with early breast cancer PRO. Siegfried Seeber*, Anja Welt**

Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)

Treatment strategy of metastatic rectal cancer

Gene Expression Profiling has been proposed as a method of risk stratification for uveal melanoma.

Liver surgery, acute GI tract bleeding

Melanoma: Therapeutic Progress and the Improvements Continue

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals

Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009

ORIGINAL ARTICLE. Summary. Introduction

The Itracacies of Staging Patients with Suspected Lung Cancer

Results of CRS and HIPEC in. Colorectal PSM. and. Pseudomyxoma Peritonei

CASE REPORT. Introduction. Case series reports. J Thorac Dis 2012;4(S1): DOI: /j.issn s003

Outcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study

Treatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy

Table S2. Expression of PRMT7 in clinical breast carcinoma samples

After primary tumor treatment, 30% of patients with malignant

The Surgical Management of Colorectal Metastases

Circulating Tumor Cells in non- Metastatic Triple Negative Breast Cancer

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

How to deal with synchronous primary and liver metastases

Pancreatic Cancer and Radiation Therapy

Current Treatment of Colorectal Metastases. Dr. Thavanathan Surgical Grand Rounds February 1, 2005

Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background

Gastrinoma: Medical Management. Haley Gallup

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

ORIGINAL ARTICLE. A Second Liver Resection Due to Recurrent Colorectal Liver Metastases. accepted as the only curative

CURRENT ISSUES IN TRANSPLANT DERMATOLOGY

Rebecca Vogel, PGY-4 March 5, 2012

Risk factors for cancer recurrence or death within 6 months after liver resection in patients with colorectal cancer liver metastasis

Results of the ACOSOG Z0011 Trial

Trattamento chirurgico delle lesioni epatiche secondarie difficili. Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica

Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?

Colorectal Liver Metastases Metachronous

Journal of Breast Cancer

Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers

HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies

Management of Cholangiocarcinoma. Roseanna Lee, MD PGY-5 Kings County Hospital

Carcinoma del colon-retto: La Chirurgia Robotica nella Malattia Avanzata

Chapter 5: Epidemiology of MBC Challenges with Population-Based Statistics

Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.

Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection

Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP

MANAGEMENT OF INCIDENTALLY DETECTED GALLBLADDER CANCER

Multidisciplinary management of retroperitoneal sarcomas

Regional Therapy for Management of Peritoneal Carcinomatosis from Gastrointestinal Malignancies

Esophageal cancer: Biology, natural history, staging and therapeutic options

Meta analysis in Rectal Cancer

Management of Perforated Colon Cancers

Pulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience

Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome

General summary GENERAL SUMMARY

Margin status in liver resections for colorectal metastases Orlando Jorge M. Torres MD, PhD

Bladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature. William Julian, MD. James J.

sarcoma Reprint requests: Dr M H Robinson, YCRC Senior Lecturer Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ.

Transcription:

Nicolae Bacalbasa Carol Davila University Of Medicine and Pharmacy

Approximately 5% to 10% of breast cancers are metastatic at diagnosis (1) 50% of breast cancer patients will develop distant metastases (2) Traditionally, the median survival rates of the untreated patients with metastatic breast cancer range between 3 and 6 months (3;4), while in patients receiving the modern oncologic treatment the median survival rates did not exceed 15 months (5; 6) 1 Cordoso F et al. Ann Oncol (2012) 23 (suppl 7):vii11-vii19. 2. Elias D. and Pietroantonio DD. HBP 2006 8 (2):97-99;. 1. Adam R, et al. Ann Surg 2006; 244(6):897-907. 4. Dimick JB, et al. Arch Surg 2003 ;138(2):185-91 5. Fisher B. et al. N Engl. Med. 2002; 347:1233-41; 6. Yoshimoto M et. al. Breast Cancer Res Treat 2000 ;59(2):177-84;

Liver resection for colo-rectal cancer liver metastases reaches a three year survival close to 50% and represents now standard of care

Median survival for liver metastases: 1-14 months (1) Median survival for lung metastases: 20-25 months (2) Median survival for bone metastases: 50-60 months (3) - Maybe liver surgery can be regarded as a method of obtaining liver disease free interval shifting survival towards survival for more preferable metastatic sites (bone) - Prevention of liver failure (1) L Wyld*,1, E Gutteridge2, SE Pinder3, JJ James4, SY Chan5, KL Cheung2, JFR Robertson2 and AJ Evans. Prognostic factors for patients with hepatic metastases from breast cancer British Journal of Cancer (2003) 89, 284 290 (2) Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN. Results and long term follow-up for 1581 patients with metastatic carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer 1999;85:104 11 (3) Sung Gwe Ahn, 1 Hak Min Lee, 1 Sang-Hoon Cho, 2 Seung Ah Lee, 1 Seung Hyun Hwang, 1 Joon Jeong, 1 and Hy-De Lee 1. Prognostic Factors for Patients with Bone-Only Metastasis in Breast Cancer, Yonsei Med J. 2013 Sep 1; 54(5): 1168 1177.

Liver resection in general is becoming safe Original Article February 2003 Hepatic Resection in the United States Indications, Outcomes, and Hospital Procedural Volumes From a Nationally Representative Database FREE Justin B. Dimick, MD; John A. Cowan Jr, MD; James A. Knol, MD; Gilbert R. Upchurch Jr, MD Background Hepatic resection has become common in theunited STATES for both primary and secondary hepatic tumors (the number of hepatectomies increased twofold, mortality decreased exponentially.

Mortality most studies report O mortality Morbidity range: 13-22%, most not requiring reoperation - Pleural effusion - Bile leak - Hematoma - Wound infection - Urinary tract infection - Pneumonia - Bile duct stenosis

- No prospective case matched study - One retrospective case matched study

- 85 patients resected for BCLM - 19 (22,3%) were treated (before hepatectomy for loco-regional recurrence - 16 (18,8%) presented extra-abdominal metastases - 14 (16,4%) presented extra-hepatic intra-abdominal metastases - Aggressive surgery achieved complete resection of metastatic burden in 50/85 patients Median survival 32 months, 5 year survival 37% from the time of hepatectomy

- Patients who responded well to neo-adjuvant chemotherapy have a good prognosis after resection - Progression under neo-adjuvant chemotherapy is the worst prognostic factor

- Timing is crucial, the best response following chemo-hormonotherapy should be obtained, but hepatectomy should be performed before chemoresistence develops

Size of the breast tumor - No study revealed any association between primary tumor size (T) and survival after resection for BCLM (1,2) Nodal status at the time of breast cancer diagnosis: - In Pocard s study liver recurrence rate was statistically higher in N1b-N2 patients than in N0-N1a patients (p=0.021) (2). 1. Belda et al Role of resection surgery in breast cancer liver metastases. Experience over the last 10 years in a reference hospital. Cir. Esp. 88(3), 167-173 (2010) 2. Pocard M et al. Hepatic resection in metastatic breast cancer: results and pprognostic factors, Eur. J. Surg Oncol. 26 92), 155-159 (2000)

Disease free interval between primary tumor resection and liver metastases diagnosis - Few studies confirm that a longer than 1 year disease free interval between breast surgery and development of BCLM is significantly associated with an improved survival (1,2) - Similar results were reported by Pocard et al in patients developing BCLM at more than 48 months (3). (1)Belda et al Role of resection surgery in breast cancer liver metastases. Experience over the last 10 years in a reference hospital. Cir. Esp. 88(3), 167-173 (2010) (2)Hoffmann et al, Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann. Surg. Oncol. 17 (6), 1546-1554 (2010) (3)Pocard M et al. Hepatic resection in metastatic breast cancer: results and pprognostic factors, Eur. J. Surg Oncol. 26 92), 155-159 (2000)

Number and diameter of liver metastases - Most studies failed to find any correlation between number/size of BCLM and survival rates after hepatectomy - The only study finding that the number of BCLM is an independent prognostic factor comes from Lubrano et al (p=0,04) (1) (1) Lubrano et al, Liver resection for breast cancer metastasis: does it improve survival? Surg. Today 38(4), 293-299 (2008)

Resection margins - Most studies revealed that patients submitted to an R0 resection have a better outcome (1,2,3) - In Hoffman s study patient submitted to R1/R2 resections were six-times more likely to die than patients submitted to an R0 resection (3) (1)Ditmar et al, Liver resection in selected patients with metastatic breast cancer: a single-center analysis and review of the literature, J. Cancer Res. Clin. Oncol. 139(8), 1317-1325 (2013) (2)Thelen et al, Liver resection for metastases from breast cancer. J. Surg. Oncol. 97(1), 25-29 (2008) (3)Hoffmann et al, Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors. Ann. Surg. Oncol. 17 (6), 1546-1554 (2010)

Primary breast tumor hormone receptor status - Many studies revealed a favorable correlation between the positive status of hormone-receptors (mainly ER) and survival after liver resection (1,2) - Elias et al revealed a relative risk of death 3,5-fold increased when hormone-receptors are negative - Abbott et al found that negative estrogen receptors are associated with decreased overall survival 1. Elias et al, An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am. J. Surg. 185(2), 158-164 (2003 2. Abbott DE et al, Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 151(5), 710-716(2012)

52 patients were proposed liver resection for BCLM - 43 patients underwent liver resections - 2 patients underwent RFA - 7 patients abdominal exploration revealed unresectable disease Excluded from the study 35 patients (81,4%) received neoadjuvant chemo/hormonotherapy prior to liver resection

Characteristics of the breast tumor

Characteristics of the liver metastases

Morbidity and mortality Mortality the 60 days following surgery = 0 Morbidity 7 patients 16,2% - Biliary leakage - Intra-abdominal abscess- 2 - Urinary infection -1 - Wound infection -1

Survival -median survival: 32,2 months (range = 3-123,7 months) Survival following breast cancer surgery following liver resection for BCLM Median survival 59,70 m 32,2 m 1 year 100% 93,02% 3 years 94,12% 74,42% 5 years 72,55% 58,14% Longest survival 255,2 m 123,7 m

Prognostic factors / who benefited the most?

Prognostic factors / who benefited the most?

Prognostic factors / who benefited the most?

Is there a place for re-resection for liver recurrence? - 6 /43 patients underwent a second liver resection - Overall survival after re-resection was 28 months (range 10-44 months) - 2 patients underwent a third resection

Long survivors

Liver resection should be considered in the multimodal treatment approach of patients with metastatic breast cancer. The treatment should be tailored to each individual patient. Surgical resection of liver metastases from primary breast cancer appears to provide a survival benefit for highly selected patients.